Related Experiment Videos
Anticoagulation minimization is safe and effective in albumin liver dialysis using the molecular adsorbent
Han Khim Tan1, Wen Shin Yang, Pierce Chow
1Department of Renal Medicine, Singapore General Hospital, Outram Road, Singapore 169608. grmthk@sgh.com.sg
Abstract:
The molecular adsorbent recirculating system (MARS) is a blood purification device with renal and hepatic dialytic effects. This study examined the use of low-dose unfractionated heparin in MARS. This was a prospective, observational study of 15 MARS treatment sessions (mean duration per treatment cycle = 12.2 +/- 4.5 h) in four patients with severe acute decompensation of chronic liver disease (n = 3) and fulminant hepatic failure (n = 1) treated with intermittent MARS. All patients were critically ill (APACHE II 24.8 +/- 3.3). Renal dialysis was with continuous hemofiltration and/or slow low-efficiency dialysis. One MARS session was terminated because of vascular access occlusion (1/15; 6.7%). Bleeding was noted in two sessions (2/15; 13%). Twelve MARS sessions were heparin-free and three treatments were with mean heparin dose of 833 +/- 382 IU. Serum biochemical parameters pre- and post-MARS were total bilirubin (micromol/L): 409.4 +/- 141.6 versus 282.9 +/- 90, P < 0.05; plasma ammonia (micromol/L): 44.3 +/- 21.2 versus 28.8 +/- 20.2, P = 0.002; urea (mmol/L): 15.9 +/- 11.8 versus 7.9 +/- 6.6, P = 0.002; creatinine (micromol/L): 252.4 +/- 151.9 versus 150.1 +/- 96.6, P = 0.003. Pre-MARS versus post-MARS systolic (SBPs) and diastolic (DBPs) blood pressures (mm Hg) were SBP = 129.2 +/- 27.7 versus 124 +/- 25, P = 0.838; and DBP = 60.7 +/- 15.3 versus 56 +/- 13, P = 0.595. Prothrombin time (PT), activated partial thromboplastin time (aPTT) and platelet count (Plt) pre- and post-MARS were PT(s): 22 +/- 7.9 versus 23.8 +/- 10.2, P = 0.116; aPTT (s): 64.5 +/- 40.9 versus 85.5 +/- 50.6, P = 0.092; and Plt (x10(3)/mm(3)): 87 +/- 67.6 versus 68.8 +/- 39, P = 0.098. MARS priming with heparin saline was safe. Heparin-minimized MARS did not compromise circuit function and longevity in extended intermittent MARS.
Insights
Low-dose heparin in molecular adsorbent recirculating system (MARS) treatments for liver failure was safe and effective. This blood purification method showed significant improvements in liver function markers without compromising the MARS circuit.
Area of Science:
- Nephrology
- Hepatology
- Critical Care Medicine
Background:
- The molecular adsorbent recirculating system (MARS) is a vital blood purification technology for patients with severe liver dysfunction.
- Heparin is commonly used to prevent clotting in extracorporeal circuits, but its use can increase bleeding risk in critically ill patients.
Purpose of the Study:
- To evaluate the safety and efficacy of using low-dose unfractionated heparin during intermittent MARS treatments in critically ill patients with liver failure.
- To assess the impact of heparin-minimized MARS on circuit function and longevity.
Main Methods:
- A prospective, observational study involving 15 MARS treatment sessions in four patients with severe acute decompensation of chronic liver disease or fulminant hepatic failure.
- MARS treatments included continuous hemofiltration and/or slow low-efficiency dialysis.
- Data collected included serum biochemical parameters, blood pressure, prothrombin time, activated partial thromboplastin time, and platelet count pre- and post-MARS.
Main Results:
- MARS priming with heparin saline was safe, with only one session terminated due to vascular access occlusion and bleeding noted in two sessions (13%).
- Significant reductions were observed in total bilirubin (P < 0.05), plasma ammonia (P = 0.002), urea (P = 0.002), and creatinine (P = 0.003) post-MARS.
- Heparin-minimized MARS did not compromise circuit function or longevity during extended intermittent treatments.
Conclusions:
- Low-dose unfractionated heparin can be safely used in MARS treatments for patients with severe liver failure.
- Heparin-minimized MARS effectively improves key biochemical markers associated with liver dysfunction.
- This approach offers a viable alternative for anticoagulation in MARS, potentially reducing bleeding complications.
Related Concept Videos
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Continuous Renal Replacement Therapy
Acute Kidney Injury V: Interprofessional Care
Venous Thrombosis III: Interprofessional Care
Acute Kidney Injury IV: Diagnostic Studies and Prevention